Methods for treating neurological conditions (WO2011159945)

Bibliography

• Gustavsson A, Svensson M, Jacobi F, Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
   PubMed Web of Science ®Google Scholar
• Meissner WG, Frasier M, Gasser T, Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-93
   PubMed Web of Science ®Google Scholar
• Boda B, Nikonenko I, Alberi S, Muller D. Central nervous system functions of PAK protein family: from spine morphogenesis to mental retardation. Mol Neurobiol 2006;34:67-80
   PubMed Web of Science ®Google Scholar
• Zhao L, Ma QL, Calon F, Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 2006;9:234-42
   PubMed Web of Science ®Google Scholar
• Kreis P, Barnier JV. PAK signalling in neuronal physiology. Cell Signal 2009;21:384-93
   PubMed Web of Science ®Google Scholar
• Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003;72:743-81
   PubMed Web of Science ®Google Scholar
• Cammarano MS, Nekrasova T, Noel B, Minden A. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol 2005;25:9532-42
   PubMedGoogle Scholar
• Huynh N, Liu KH, Baldwin GS, He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta 2010;1803:1106-13
   PubMed Web of Science ®Google Scholar
• Daniels RH, Hall PS, Bokoch GM. Membrane targeting of p21-activated kinase 1 (PAK1) induces neurite outgrowth from PC12 cells. EMBO J 1998;17:754-64
   PubMed Web of Science ®Google Scholar
• Bryan B, Kumar V, Stafford LJ, GEFT, a Rho family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation. J Biol Chem 2004;279:45824-32
   PubMed Web of Science ®Google Scholar
• Rashid T, Banerjee M, Nikolic M. Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J Biol Chem 2001;276:49043-52
   PubMed Web of Science ®Google Scholar
• Kichina JV, Goc A, Al-Husein B, PAK1 as a therapeutic target. Expert Opin Ther Targets 2010;14:703-25
   PubMed Web of Science ®Google Scholar
• Shin EY, Shin KS, Lee CS, Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem 2002;277:44417-30
   PubMed Web of Science ®Google Scholar
• Buchner DA, Su F, Yamaoka JS, pak2a mutations cause cerebral hemorrhage in redhead zebrafish. Proc Natl Acad Sci USA 2007;104:13996-4001
   PubMed Web of Science ®Google Scholar
• Liu J, Fraser SD, Faloon PW, A betaPix Pak2a signaling pathway regulates cerebral vascular stability in zebrafish. Proc Natl Acad Sci USA 2007;104:13990-5
   PubMed Web of Science ®Google Scholar
• Boda B, Alberi S, Nikonenko I, The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus. J Neurosci 2004;24:10816-25
   PubMed Web of Science ®Google Scholar
• Zhang H, Webb DJ, Asmussen H, A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and synapse formation through MLC. J Neurosci 2005;25:3379-88
   PubMed Web of Science ®Google Scholar
• Hayashi ML, Choi SY, Rao BS, Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice. Neuron 2004;42:773-87
   PubMed Web of Science ®Google Scholar
• Purpura DP. Dendritic spine "dysgenesis" and mental retardation. Science 1974;186:1126-8
   PubMed Web of Science ®Google Scholar
• Danzer KM, Schnack C, Sutcliffe A, Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers. J Neurochem 2007;103:2401-7
   PubMed Web of Science ®Google Scholar
• Sredni B, Geffen-Aricha R, Duan W, Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB J 2007;21:1870-83
   PubMed Web of Science ®Google Scholar
• Crawford JJ, Hoeflich KP, Rudolph J. p21-Activated kinase inhibitors: a patent review. Expert Opin Ther Pat 2012;22:293-310
   PubMed Web of Science ®Google Scholar
• Stephens B, Mueller AJ, Shering AF, Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005;132:741-54
   PubMed Web of Science ®Google Scholar
• Zaja-Milatovic S, Milatovic D, Schantz AM, Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545-7
   PubMed Web of Science ®Google Scholar
• Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007;13(Suppl 3):S251-8
   Web of Science ®Google Scholar
• Schuster S, Doudnikoff E, Rylander D, Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 2009;65:518-26
   PubMed Web of Science ®Google Scholar
• Bezard E. Treating Parkinson's disease: preserve the spines! (Commentary on Soderstrom et al.). Eur J Neurosci 2010;31:477
   PubMed Web of Science ®Google Scholar
• McKeith I, Mintzer J, Aarsland D, Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28
   PubMed Web of Science ®Google Scholar
• Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-10
   PubMed Web of Science ®Google Scholar
• Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010;120:131-43
   PubMed Web of Science ®Google Scholar
• Bellucci A, Navarria L, Zaltieri M, Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 2012;1432:95-113
   PubMed Web of Science ®Google Scholar
• Bellucci A, Zaltieri M, Navarria L, From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012; dx.doi.org/10.1016/j.brainres.2012.04.014
   Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7
   PubMed Web of Science ®Google Scholar
• Lesage S, Ibanez P, Lohmann E, G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-7
   PubMed Web of Science ®Google Scholar
• Chan D, Citro A, Cordy JM, Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 2011;286:16140-9
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91
   PubMed Web of Science ®Google Scholar
• Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 2004;33:377-87
   PubMedGoogle Scholar
• Terry RD, Masliah E, Salmon DP, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Galvan V, Huang W, Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem 2008;104:1065-80
   Google Scholar
• Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog Neurobiol 2012; dx.doi.org/10.1016/j.bbr.2011.03.031
   PubMed Web of Science ®Google Scholar
• Sotrel A, Williams RS, Kaufmann WE, Myers RH. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. Neurology 1993;43:2088-96
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Kowall NW, Richardson EP Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 1991;11:3877-87
   PubMed Web of Science ®Google Scholar
• Wang HF, Shih YT, Chen CY, Valosin-containing protein and neurofibromin interact to regulate dendritic spine density. J Clin Invest 2011;121:4820-37
   PubMed Web of Science ®Google Scholar
• Lin YL, Lei YT, Hong CJ, Hsueh YP. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway. J Cell Biol 2007;177:829-41
   PubMed Web of Science ®Google Scholar
• Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010;37:596-603
   PubMed Web of Science ®Google Scholar
• Russo SJ, Dietz DM, Dumitriu D, The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci 2010;33:267-76
   PubMed Web of Science ®Google Scholar
• Afraxis, Inc. A. Methods for treating neurological conditions. WO2011159945; 2011
   Google Scholar
• Zhao ZS, Manser E, Chen XQ, A conserved negative regulatory region in alphaPAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol Cell Biol 1998;18:2153-63
   PubMed Web of Science ®Google Scholar
• Hayashi ML, Rao BS, Seo JS, Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA 2007;104:11489-94
   PubMed Web of Science ®Google Scholar
• Luo S, Mizuta H, Rubinsztein DC. p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity. Hum Mol Genet 2008;17:895-905
   Google Scholar
• Luo S, Rubinsztein DC. Huntingtin promotes cell survival by preventing Pak2 cleavage. J Cell Sci 2009;122:875-85
   Google Scholar
• Dubos A, Combeau G, Bernardinelli Y, Alteration of synaptic network dynamics by the intellectual disability protein PAK3. J Neurosci 2012;32:519-27
   Google Scholar
• Irwin SA, Patel B, Idupulapati M, Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 2001;98:161-7
   PubMed Web of Science ®Google Scholar
• Costa RM, Federov NB, Kogan JH, Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002;415:526-30
   PubMed Web of Science ®Google Scholar
• Yi C, Wilker EW, Yaffe MB, Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res 2008;68:7932-7
   Google Scholar